Spyre Therapeutics Stock Rallies as Investor Focus Shifts to IBD Pipeline

Spyre Therapeutics (NASDAQ: SYRE) stock climbed 7.0% in morning trading, staging a recovery after a significant decline caused by mixed clinical trial results. Investors are now reassessing the company's value, pivoting their attention from a recent data release to the potential of Spyre's broader drug pipeline, particularly its treatments for inflammatory bowel disease (IBD).

Shifting Focus After Mixed Data

The recent sell-off was triggered by mixed Phase 2 data from the SKYWAY trial, which evaluated the company's drug candidate SPY072 in patients with rheumatoid arthritis. Following this event, the market has shifted its focus to what many analysts see as the primary long-term value driver: Spyre's IBD pipeline. The company's SKYLINE program, in particular, is viewed as a more compelling asset based on its strong proof-of-concept data, according to an Investing.com report.

Wall Street Support and Financial Position

Analyst sentiment remains a key pillar of support for the stock. According to the source, investment firms have maintained positive outlooks despite the recent trial results:

Ad

• Wedbush reiterated its Outperform rating with a $123 price target on September 9.
• Guggenheim reiterated its Buy rating with a $130 price target, specifically citing the company's focus on IBD.

Adding to investor confidence is the company's strong financial health. Spyre has reported a cash runway extending into the second half of 2029, which mitigates near-term financing risks and provides capital to advance its clinical programs through their 2026 data readouts.

Market Context and Outlook

The rally is also supported by a constructive broader market, with the Nasdaq Composite advancing over 1.0% and the S&P 500 gaining 0.6%. As a high-beta stock, Spyre tends to amplify broader market movements, and the positive sentiment is helping its shares recover from technically oversold levels. Looking ahead, investors are anticipating further data from the SKYWAY trial in the fourth quarter of 2026, including readouts for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).